Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Precision Biosciences (DTIL) Cash from Operations (2018 - 2025)

Historic Cash from Operations for Precision Biosciences (DTIL) over the last 8 years, with Q3 2025 value amounting to -$15.3 million.

  • Precision Biosciences' Cash from Operations fell 15828.82% to -$15.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$73.3 million, marking a year-over-year decrease of 5207.22%. This contributed to the annual value of -$58.4 million for FY2024, which is 3051.69% up from last year.
  • Precision Biosciences' Cash from Operations amounted to -$15.3 million in Q3 2025, which was down 15828.82% from -$20.3 million recorded in Q2 2025.
  • Precision Biosciences' Cash from Operations' 5-year high stood at $68.1 million during Q1 2021, with a 5-year trough of -$31.5 million in Q1 2023.
  • Moreover, its 5-year median value for Cash from Operations was -$20.3 million (2025), whereas its average is -$13.4 million.
  • Its Cash from Operations has fluctuated over the past 5 years, first skyrocketed by 36272.48% in 2021, then plummeted by 17912.36% in 2023.
  • Precision Biosciences' Cash from Operations (Quarter) stood at -$23.7 million in 2021, then increased by 7.76% to -$21.8 million in 2022, then surged by 61.44% to -$8.4 million in 2023, then crashed by 121.81% to -$18.7 million in 2024, then grew by 18.27% to -$15.3 million in 2025.
  • Its Cash from Operations was -$15.3 million in Q3 2025, compared to -$20.3 million in Q2 2025 and -$19.1 million in Q1 2025.